The Sarah Cannon Research Institute joined Strata Oncology Inc.’s Precision Indications for Approved THerapies (NCT05097599) trial.
The WiTT Group and Mary Crowley Cancer Research form partership to enhance access to clinical trials
The WiTT Group Inc., a company focused on solving the non-clinical challenges patients face as they go through cancer treatment, formed a partnership Mary Crowley Cancer Research to identify and help patients gain access to clinical trials.
Phase I/II ARROW trial results show that pralsetinib, a highly selective RET inhibitor, was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type.
Results from the phase III 006 Study of Cytalux (pafolacianine) injection for intraoperative imaging of folate receptor positive ovarian cancer reports that use of Cytalux during ovarian cancer surgery demonstrated identification of additional lesions that were not identified with conventional means and not otherwise planned for resection.
A study led by researchers at NCI demonstrated that older adults who participate weekly in many different types of leisure time activities, such as walking for exercise, jogging, swimming laps, or playing tennis, may have a lower risk of death from any cause, as well as death from cardiovascular disease and cancer.
Young B-ALL patients who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range.
Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard, along with clinicians at Washington University in St. Louis have identified biological markers in triple negative breast cancer that are associated with resistance to chemotherapy treatment.
Updated data from the ongoing GEMSTONE-301 phase III study demonstrated a statistically significant improvement in PFS in unresectable stage III NSCLC patients treated with sugemalimab when administered after treatment with either concurrent or sequential chemoradiotherapy.
Research suggests that emergency response personnel, recovery workers, law enforcement, and construction workers who reported to the World Trade Center disaster site were exposed to carcinogens that doubled their risk of developing myeloma.
Keck School of Medicine of USC researchers find that a common man-made polyfluoroalkyl substance (PFAS) may elevate risk of liver cancer.
